Insurance
Home›Insurance›Health Insurance›Sun Life says GLP-1 coverage should be treated as risk…
Sun Life says GLP-1 coverage should be treated as risk management
Sun Life data cited by the insurer shows GLP-1 claim volume rose 24% in one year, while liver disease spending increased 43% year over year to $63.9 million.
Insurance Business reports that a Sun Life US executive says employer debate about GLP-1 coverage has overly focused on pharmacy costs, arguing that the issue should be framed as cardiometabolic risk management instead.
According to Sun Life claims data discussed in the interview, GLP-1 claim volume rose 24% in a single year. The same dataset showed hepatic liver disease spend climbed 43% year over year to $63.9 million, and the average claimant cost reached $230,000.
Insurance Business adds that Sun Life’s High Cost Trend Report highlights comorbidity overlap tied to GLP-1 coverage, positioning the decision as risk management rather than only drug spend. Jennifer Collier, President of Health and Risk Solutions at Sun Life US, said employers should consider GLP-1 plans through that risk lens.
The outlet also notes Collier spoke about how benefit brokers can help reshape plan design and employer conversations around GLP-1 coverage, including the use of second opinions.